Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2016 7
2017 8
2018 7
2019 19
2020 16
2021 27
2022 36
2023 44
2024 16
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 36581373

138 results

Results by year

Filters applied: . Clear all
Page 1
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria.
Gafita A, Rauscher I, Fendler WP, Murthy V, Hui W, Armstrong WR, Herrmann K, Weber WA, Calais J, Eiber M, Weber M, Benz MR. Gafita A, et al. Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):4271-4281. doi: 10.1007/s00259-022-05882-x. Epub 2022 Jun 29. Eur J Nucl Med Mol Imaging. 2022. PMID: 35767071
Therapeutic efficacy, prognostic variables and clinical outcome of 177Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohort.
Suman S, Parghane RV, Joshi A, Prabhash K, Bakshi G, Talole S, Banerjee S, Basu S. Suman S, et al. Br J Radiol. 2019 Dec;92(1104):20190380. doi: 10.1259/bjr.20190380. Epub 2019 Nov 1. Br J Radiol. 2019. PMID: 31600089 Free PMC article.
Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study.
Gafita A, Rauscher I, Weber M, Hadaschik B, Wang H, Armstrong WR, Tauber R, Grogan TR, Czernin J, Rettig MB, Herrmann K, Calais J, Weber WA, Benz MR, Fendler WP, Eiber M. Gafita A, et al. J Nucl Med. 2022 Nov;63(11):1651-1658. doi: 10.2967/jnumed.121.263072. Epub 2022 Apr 14. J Nucl Med. 2022. PMID: 35422442 Free PMC article.
Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy.
Rosar F, Wenner F, Khreish F, Dewes S, Wagenpfeil G, Hoffmann MA, Schreckenberger M, Bartholomä M, Ezziddin S. Rosar F, et al. Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1584-1594. doi: 10.1007/s00259-021-05594-8. Epub 2021 Nov 2. Eur J Nucl Med Mol Imaging. 2022. PMID: 34725725 Free PMC article.
The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN).
Pathmanandavel S, Crumbaker M, Nguyen A, Yam AO, Wilson P, Niman R, Ayers M, Sharma S, Eu P, Martin AJ, Stockler MR, Joshua AM, Emmett L. Pathmanandavel S, et al. J Nucl Med. 2023 Jan;64(1):69-74. doi: 10.2967/jnumed.122.264104. Epub 2022 Jun 23. J Nucl Med. 2023. PMID: 35738906 Free PMC article. Clinical Trial.
Change in total lesion PSMA (TLP) during [177Lu]Lu-PSMA-617 radioligand therapy predicts overall survival in patients with mCRPC: monocentric evaluation of a prospective registry.
Burgard C, Hein C, Blickle A, Bartholomä M, Maus S, Petto S, Schaefer-Schuler A, Ezziddin S, Rosar F. Burgard C, et al. Eur J Nucl Med Mol Imaging. 2024 Feb;51(3):885-895. doi: 10.1007/s00259-023-06476-x. Epub 2023 Oct 27. Eur J Nucl Med Mol Imaging. 2024. PMID: 37889298 Free PMC article.
138 results